Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

My previous session
Most popular
Real-time Quote. Real-time Tradegate - 08/14 03:36:28 pm
73.155 EUR   -0.46%
08/13SANOFI : Disclosure of trading in own shares
08/07Biotech entrepreneur Drayson plans to list new AI drug research f..
08/07SANOFI : Shanghai Junshi planning Hong Kong IPO
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Reports Outline Medicinal Chemistry Study Results from Sanofi (Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum)

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:30pm CEST

By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Medicinal Chemistry have been published. According to news reporting originating in Frankfurt, Germany, by NewsRx journalists, research stated, "The scientific advances being made across all disciplines are creating ever-increasing opportunities to enhance our knowledge of biological systems and how they relate to human disease. One of the central driving forces in discovering new medicines is medicinal chemistry, where the design and synthesis of novel compounds has led to multiple drugs."

The news reporters obtained a quote from the research from Sanofi, "Chemical biology, sitting at the interface of many disciplines, has now emerged as a major contributor to the understanding of biological systems and is becoming an integral part of drug discovery. Bringing chemistry and biology much closer and blurring the boundaries between disciplines is creating new opportunities to probe and understand biology; both disciplines play key roles and need to join forces and work together effectively to synergize their impact. The power of chemical biology will then reach its full potential and drive innovation, leading to the discovery of transformative medicines to treat patients."

According to the news reporters, the research concluded: "Advances in cancer biology and drug discovery highlight this potential."

For more information on this research see: Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum. Cell Chemical Biology, 2017;24(9):1058-1065. Cell Chemical Biology can be contacted at: Cell Press, 50 Hampshire St, Floor 5, Cambridge, MA 02139, USA (see also Medicinal Chemistry).

Our news correspondents report that additional information may be obtained by contacting A.T. Plowright, Sanofi Aventis Deutschland GmbH, Integrated Drug Discovery, D-65926 Frankfurt, Germany. Additional authors for this research include C. Ottmann, M. Arkin, Y.P. Auberson, H. Timmerman and H. Waldmann.

Keywords for this news article include: Frankfurt, Germany, Europe, Medicinal Chemistry, Chemical Biology, Chemicals, Sanofi.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
08/13SANOFI : Disclosure of trading in own shares
08/11SANOFI : Early Phase Results Promising for BTK Inhibitor in Multiple Sclerosis T..
08/10SANOFI : Polluting Sanofi factory allowed to partially resume manufacturing
08/09SANOFI : Recent Studies from Sanofi Pasteur Add New Data to Hepatitis (Host cell..
08/09SANOFI : Study Findings on Eye Proteins Are Outlined in Reports from Sanofi (Com..
08/09SANOFI : Studies from Sanofi Pasteur Have Provided New Data on Dengue Hemorrhagi..
08/09SANOFI : Studies from Genzyme Corporation Update Current Data on Type 1 Diabetes..
08/07Biotech entrepreneur Drayson plans to list new AI drug research firm
08/07SANOFI : Shanghai Junshi planning Hong Kong IPO
08/06SANOFI : Disclosure of trading in own shares
More news
News from SeekingAlpha
08/13Amicus Receives First FDA Approval For Fabry Disease Treatment In 15 Years 
08/13Alnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare D.. 
08/10Premarket analyst action - healthcare 
08/09U.S. Moats Ahead Despite IT Underweight 
08/09BeiGene launches late-stage study of tislelizumab in first-line lung cancer 
At a Crossroads
Financials (€)
Sales 2018 35 035 M
EBIT 2018 8 521 M
Net income 2018 5 102 M
Debt 2018 16 254 M
Yield 2018 4,18%
P/E ratio 2018 17,81
P/E ratio 2019 16,71
EV / Sales 2018 3,10x
EV / Sales 2019 2,99x
Capitalization 92 251 M
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 79,6 €
Spread / Average Target 8,2%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI2.28%105 151
JOHNSON & JOHNSON-6.42%350 770
PFIZER13.00%239 423
NOVARTIS-0.87%209 596
ROCHE HOLDING LTD.-3.39%207 317
MERCK AND COMPANY17.42%175 715